# Chronic Coronary Syndrome

> Chronic coronary syndrome for NEET-SS Cardiology: medical therapy first, ISCHEMIA and COURAGE, revascularisation timing and DAPT duration.

- Canonical URL: https://prepelephant.com/topics/neet-ss/cardiology/chronic-coronary-syndrome
- Exam / course: NEET-SS · Subject: Cardiology
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-02
- Last updated: 2026-10-02
- How to cite: "Chronic Coronary Syndrome", PrepElephant, https://prepelephant.com/topics/neet-ss/cardiology/chronic-coronary-syndrome

## Direct answer

The ISCHEMIA trial reframed how chronic coronary syndrome (the 2019 ESC term replacing "stable coronary artery disease") is managed: among patients with moderate-to-severe ischaemia on non-invasive testing, an initial invasive strategy of catheterisation and revascularisation did not reduce death or myocardial infarction compared with optimal medical therapy, though it relieved angina better. First-line treatment is therefore medical — aspirin, a high-intensity statin, an ACE inhibitor where indicated, and anti-anginals (beta-blocker first, then calcium-channel blocker, long-acting nitrate, nicorandil or ranolazine). Revascularisation is reserved for symptoms refractory to two anti-anginals, or high-risk anatomy: left main disease, three-vessel disease, proximal LAD involvement, or ischaemic burden above 10 per cent of the myocardium.

## What you must remember

- **Terminology:** "stable CAD" is now chronic coronary syndrome — six clinical scenarios from stable angina to asymptomatic post-revascularisation states; the exam still tests the 2019 ESC shift.
- **Optimal medical therapy:** aspirin 75-100 mg, high-intensity statin regardless of baseline LDL (aim: at least 50 per cent LDL reduction), ACE inhibitor or ARB in hypertension, diabetes or CKD, plus symptom-directed anti-anginals.
- **ISCHEMIA (2020):** routine invasive strategy gave no reduction in death or MI at median 3.3 years, but better daily angina control — COURAGE (2007) had already shown PCI adds no prognostic benefit over medical therapy in stable disease.
- **Prognostic indications for revascularisation:** left main stenosis, three-vessel disease (especially with reduced LVEF or diabetes), proximal LAD, large ischaemic territory (>10 per cent) on imaging.
- **Diagnostic pathway:** pre-test probability first; CT coronary angiography in low-to-intermediate probability (SCOT-HEART: fewer fatal and non-fatal MIs with CTCA-guided management), functional imaging (stress CMR, SPECT, stress echo) in higher probability.
- **DAPT after elective PCI:** 6 months of aspirin plus clopidogrel (1 month acceptable with high bleeding risk); 12 months after ACS.
- **Risk factor targets:** blood pressure below 130/80, HbA1c individualised, smoking cessation, cardiac rehabilitation referral — the intervention most reliably skipped in Indian practice.

## How to work through a stable chest pain case

Start with the pre-test probability, not the angiogram. A 55-year-old man with typical exertional chest pain has a high probability, so send him straight to functional imaging or invasive angiography; a 45-year-old woman with atypical pain goes to CT coronary angiography first, because her probability of obstructive disease is low and a normal or non-obstructive scan safely ends the ischaemic work-up.

If an intermediate 50-70 per cent stenosis turns up, measure its physiology — FFR at or below 0.80 or iFR at or below 0.89 — before stenting. Once obstructive disease is confirmed, decide whether revascularisation is prognostic (left main, three-vessel, proximal LAD, large ischaemia) or purely symptomatic. In the purely symptomatic case, optimise medical therapy with two anti-anginals before offering PCI, and document why. Every patient leaves on a statin, aspirin where tolerated, and a structured follow-up plan; this is the sequence the examiners want to see articulated, not "cath everyone".

## How the exam frames it

The trap is over-reading ISCHEMIA as "PCI is useless in stable disease". The correct statement is narrower: routine invasive management does not reduce death or MI in patients with moderate-to-severe ischaemia but stable symptoms, yet improves quality of life and remains indicated for refractory angina and high-risk anatomy. A favourite vignette contrasts two patients — one with anterior ischaemia over 15 per cent of the myocardium and reduced LVEF (revascularise, prognostic benefit), and one with single-vessel disease controlled on a beta-blocker (medical therapy). The Indian reality adds a second layer: direct-to-angiography pathways in private hospitals make the ISCHEMIA message clinically relevant here, since asymptomatic or mildly symptomatic patients frequently undergo multi-lesion PCI without any physiology measurement or documented anti-anginal trial.

## Frequently asked questions

### What did the ISCHEMIA trial actually show?

In stable patients with moderate-to-severe inducible ischaemia, an initial invasive strategy did not reduce death or myocardial infarction versus optimal medical therapy, but did improve angina-related quality of life.

### When is revascularisation prognostic rather than just symptomatic?

Left main stenosis, three-vessel disease (particularly with diabetes or reduced LVEF), proximal LAD disease, and ischaemia involving more than 10 per cent of the myocardium.

### How long should DAPT continue after elective stenting?

Six months of aspirin plus clopidogrel is standard for chronic coronary syndrome, shortened to 1-3 months with high bleeding risk and extended toward 12 months if an ACS intervened.

### Which non-invasive test first for suspected chronic coronary syndrome?

CT coronary angiography for low-to-intermediate pre-test probability; functional imaging such as stress CMR or SPECT when probability is higher or CT is unsuitable.

### Why did the ESC rename stable coronary artery disease?

To emphasise that atherosclerosis is a dynamic, modifiable disease with fluctuating phases rather than a fixed "stable" state, aligning management with long-term risk control.